

**What is claimed is:**

- 5 1. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
2. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate in crystalline  
10 form, having a melting point of  $T_{m.p.} = 305 \pm 5^{\circ}\text{C}$  (determined by DSC; evaluation using peak-maximum; heating rate:  $10^{\circ}\text{C}/\text{min}$ ).
3. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate  
15 according to claim 2, the X-ray powder diagram of which includes, *inter alia*, the characteristic values  $d = 5.43 \text{ \AA}$ ,  $5.08 \text{ \AA}$ ,  $4.71 \text{ \AA}$ ,  $4.50 \text{ \AA}$  and  $4.43 \text{ \AA}$  with an intensity of more than 40%.
4. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate  
20 according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions:  
 $a = 16.332 \text{ \AA}$ ,  
 $b = 19.199 \text{ \AA}$ ,  
 $c = 11.503 \text{ \AA}$ ,  
25  $\alpha = 95.27^{\circ}$ ,  
 $\beta = 90.13^{\circ}$ ,  
 $\gamma = 110.83^{\circ}$  and  
 $V = 3354.4 \text{ \AA}^3$
- 30 5. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate according to one of claims 2 to 4, in the form of the hemihydrate.
6. A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-

methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and one or more inert carriers and/or diluents.

7. A metabolite of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
8. A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.
9. A method for treating excessive or abnormal cell proliferation which comprises administering a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.